Molecule intelOpportunity: ModerateEssentialCrowded market

Sofosbuvir

173 brands · 53 companies · product forms

ATC: J05AP08 3 DRAP alerts

Opportunity snapshot

Launch attractiveness
35
Market saturation
100
Price room
100
Regulatory risk
80
173
brands
53
companies
Rs 12,119.2
median price
168
price points
105.07x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 6%

Price room

Across observed sources and strengths
CheapestRs 583.57
MedianRs 12,119.2
Most expensiveRs 61,317.23
Spread105.07×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 105.07x across 168 trusted points (Rs 583.57-61317.23). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Sofosbuvir — each links to its own medicine page.

Regulatory alerts

latest 2026-07-06
National Pharmacovigilance Cell (NPC), DRAP released a revised draft of Guidelines on Nati
National Pharmacovigilance Cell (NPC), DRAP released draft Guidelines on National Pharmaco
National Pharmacovigilance Cell (NPC), DRAP released draft Guidelines on National Pharmaco

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(0) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

53 canonical companies and 173 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 105.07x across 168 trusted points (Rs 583.57-61317.23). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

3 DRAP alert(s), latest 2026-07-06.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.